SpringerPlus

Table 3 Doxorubicin and doxorubicinol pharmacokinetics (geometric mean+/−standard error)

From: Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment

	Doxorubicin		Doxorubicinol
	With enalapril	Without enalapril	With enalapril	Without enalapril
Cmax (ng/mL)	88.79 ± 0.30	79.96 ± 5.16	27.81 ± 3.59	29.66 ± 4.68
AUC_(0-∞) ng-hr/mL	1185.56 ± 44.64	1167.73 ± 45.26	1040 ± 80.6	1056.32 ± 92.03

Back to article page